Nationwide Fund Advisors acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 40,137 shares of the biopharmaceutical company’s stock, valued at approximately $111,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp grew its position in Catalyst Pharmaceuticals by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 2,404 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in Catalyst Pharmaceuticals during the second quarter valued at approximately $149,000. JPMorgan Chase & Co. purchased a new position in Catalyst Pharmaceuticals during the first quarter valued at approximately $155,000. Rhumbline Advisers purchased a new position in Catalyst Pharmaceuticals during the second quarter valued at approximately $209,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in Catalyst Pharmaceuticals during the second quarter valued at approximately $333,000. 39.55% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) opened at $3.06 on Tuesday. Catalyst Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $3.24.

In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany bought 20,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, September 5th. The stock was purchased at an average cost of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the purchase, the insider now directly owns 4,471,026 shares of the company’s stock, valued at $11,535,247.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.60% of the stock is owned by insiders.

A number of brokerages recently commented on CPRX. Zacks Investment Research downgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 10th. SunTrust Banks, Inc. set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 31st. Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $5.50.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/40137-shares-in-catalyst-pharmaceuticals-inc-cprx-purchased-by-nationwide-fund-advisors/1717038.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.